Hip fracture patients are not treated for osteoporosis: A call to action
Article first published online: 12 DEC 2002
Copyright © 2002 by the American College of Rheumatology
Arthritis Care & Research
Volume 47, Issue 6, pages 651–654, 15 December 2002
How to Cite
Harrington, J. T., Broy, S. B., Derosa, A. M., Licata, A. A. and Shewmon, D. A. (2002), Hip fracture patients are not treated for osteoporosis: A call to action. Arthritis & Rheumatism, 47: 651–654. doi: 10.1002/art.10787
- Issue published online: 12 DEC 2002
- Article first published online: 12 DEC 2002
- Manuscript Accepted: 23 APR 2002
- Manuscript Received: 28 AUG 2001
- North Central Osteoporosis Board, the Alliance for Better Bone Health (Procter & Gamble and Aventis Pharmaceuticals)
- Hip fracture
To determine whether hip fracture patients, a group at very high risk for additional fragility fractures, are being evaluated and treated effectively for osteoporosis.
Clinical and bone densitometry (dual x-ray absorptiometry [DXA]) records were reviewed in hip fracture patients at 4 Midwestern US health systems to determine the frequency of DXA use, calcium and vitamin D supplementation, and antiresorptive drug treatment.
DXA was performed at the 4 study sites in only 12%, 12%, 13%, and 24% of patients, respectively. Calcium and vitamin D supplements were prescribed in 27%, 1%, 3%, and 25% of the patients at the 4 study sites. Antiresorptive drugs were prescribed in 26%, 12%, 7%, and 37% of the patients with only 2–10% receiving a bisphosphonate.
Reducing osteoporotic fractures will require more effective approaches to managing hip fracture patients and other high-risk populations.